Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Giancarlo Comi, Francesco Patti, Maria Assunta Rocca, Flavia Caterina Mattioli, Maria Pia Amato, Paolo Gallo, Diego Centonze, Carlo Pozzilli, Francesco Saccà, Florian Then Bergh, Marta Bartezaghi, Renato Turrini, Massimo Filippi, Francesco Patti, Clara Grazia Chisari, Girolama Alessandra Marfia, Diego Centonze, Vincenzo Brescia Morra, Ruggero Capra, Carlo PozzilliValentina Bianchi, Angelo Ghezzi, Marco Roscio, Giancarlo Comi, Francesca Sangalli, Erika Pietrolongo, Ada Francia, Maura Chiara Danni, Ugo Nocentini, Placido Bramanti, Gioacchino Tedeschi, Davide Maimone, Luigi Maria Edoardo Grimaldi, Elio Angelo Scarpini, Antonio Uccelli, Maria Pia Amato, Mariarosa Rottoli, Stefano Ruggieri, Maria Trojano, Roberto Bergamaschi, Florian Then Bergh, Mathias Buttmann, Peter Rieckmann, Ali Safavi, For the Golden Study Group

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)'. Together they form a unique fingerprint.

Medicine & Life Sciences